ERG4 Antibody

What is ERG4 and what cellular functions does it perform?

ERG4 (also known as Erg4p in yeast) is a C-24(28) sterol reductase that functions as a seven-transmembrane domain protein catalyzing the final step of ergosterol biosynthesis in the yeast endoplasmic reticulum (ER) . In filamentous fungi like Penicillium expansum, multiple variants exist (erg4A, erg4B, and erg4C) with functional redundancy but different expression levels . In human contexts, ERG proteins (such as the ERG transcription factor studied in prostate cancer) function as transcriptional regulators .

How is ERG4 protein localized within cells?

In yeast, ERG4 primarily localizes to the endoplasmic reticulum membrane, with particularly strong presence in the perinuclear ER region. This localization is consistent with its role in ergosterol biosynthesis . When tagged with GFP, wild-type Erg4p colocalizes with ER markers such as HDEL-DSRED, confirming its residence in the ER membrane system .

What are the expression patterns of different ERG4 variants in fungi?

In Penicillium expansum, the three ERG4 variants show significantly different expression patterns:

These expression differences suggest specialized functions or regulation among the variants despite their functional redundancy .

What factors should researchers consider when selecting an antibody for ERG4/ERG detection?

When selecting an antibody for ERG4/ERG detection, researchers should consider:

• Species-specificity: Determine if the antibody recognizes fungal ERG4 or human ERG proteins

• Epitope location: Consider whether the antibody targets a conserved or variable region

• Application compatibility: Verify validation for your intended application (Western blot, immunofluorescence, etc.)

• Cross-reactivity: Check for potential cross-reactivity with related proteins, particularly important in organisms with multiple ERG4 variants

• Clone type: Monoclonal antibodies offer higher specificity while polyclonal antibodies may provide stronger signals

How can researchers validate the specificity of an ERG4/ERG antibody?

Antibody validation should include multiple approaches:

• Use knockout/knockdown controls: Test antibody in cells where the target gene has been deleted or suppressed

• Perform peptide competition assays: Pre-incubate antibody with immunizing peptide to confirm specificity

• Test multiple antibody dilutions: Establish optimal signal-to-noise ratios

• Compare localization patterns: Verify that staining matches expected subcellular distribution

• Perform complementation tests: Restore expression in knockout cells and confirm signal recovery

What are the common epitopes targeted in ERG antibodies?

For human ERG antibodies, epitopes are often selected from regions that distinguish ERG from related ETS family transcription factors. For fungal ERG4, antibodies typically target regions within the catalytic domain that are conserved across fungal species but distinct from mammalian sterol reductases. When researching ERG4 in yeast, antibodies against regions between Gln26-Arg649 (similar to the range used for ErbB4 antibodies) may provide good specificity .

How can researchers use immunofluorescence to study ERG4/ERG localization?

For optimal immunofluorescence results:

• Fixation: Use 4% paraformaldehyde to preserve membrane structure

• Permeabilization: Gentle detergents like 0.1% Triton X-100 allow antibody access to ER membranes

• Blocking: Use 5% BSA or serum matching secondary antibody species

• Primary antibody: Incubate at optimal concentration (e.g., 10 μg/mL for 3 hours at room temperature)

• Secondary antibody: Use fluorophore-conjugated antibodies appropriate for your microscopy setup

• Counterstaining: DAPI for nuclei visualization

• Controls: Include ER markers (e.g., HDEL-tagged proteins) for colocalization analysis

ERG4 should show strong colocalization with ER markers, particularly in the perinuclear region .

What are the optimal methods for detecting ERG4/ERG by Western blotting?

For effective Western blot detection:

• Sample preparation:

  • For membrane proteins like ERG4, include membrane fractionation steps

  • Use appropriate detergents (RIPA buffer with 1% NP-40 or Triton X-100)

  • Include protease inhibitors to prevent degradation

• Gel selection:

  • Use 8-10% SDS-PAGE gels for optimal resolution

  • Consider gradient gels for better separation

• Transfer conditions:

  • Extend transfer time for membrane proteins (90-120 minutes)

  • Use methanol-containing transfer buffer for transmembrane proteins

• Detection optimization:

  • Test antibody dilutions to find optimal concentration

  • Longer exposure times may be necessary for lower abundance proteins

  • Consider enhanced chemiluminescence detection systems

Western blot analysis has been successfully used to detect changes in Erg4p expression in various yeast mutants .

How can researchers study ERG4 mRNA localization alongside protein expression?

Based on methodologies in the literature:

• MS2 tagging system:

  • Tag ERG4 mRNA with 12 MS2 stem-loops

  • Coexpress GFP-MCP (MS2 coat protein) fusion protein

  • Visualize ER with markers like Scs2-TMD-2×RFP

• Polysome profiling:

  • Fractionate cell lysates on sucrose gradients

  • Analyze ERG4 mRNA distribution across monosome and polysome fractions

  • Compare profiles between wild-type and mutant strains

• Combined protein-RNA analysis:

  • Perform fluorescence in situ hybridization (FISH) for mRNA

  • Combine with immunofluorescence for protein detection

  • Use confocal microscopy for colocalization analysis

This approach has revealed that in wild-type yeast cells, approximately 86.6% of ERG4-MS2 RNA particles localize at or near the ER .

How can researchers troubleshoot low signal when detecting ERG4/ERG protein?

When facing detection challenges:

• Protein extraction optimization:

  • For membrane proteins like ERG4, use specialized extraction buffers

  • Consider detergent screening (CHAPS, digitonin, DDM) to find optimal solubilization

  • Include proteasome inhibitors (MG132) as ERG4 may undergo rapid degradation

• Antibody optimization:

  • Test different antibody concentrations and incubation times

  • Try different blocking agents to reduce background

  • Consider signal amplification techniques (HRP-polymer systems, tyramide amplification)

• Sample handling:

  • Minimize freeze-thaw cycles

  • Process samples quickly to prevent degradation

  • Consider enrichment strategies for membrane proteins

In yeast studies, western blot analysis showed weaker expression of Erg4-yeGFP in bfr1Δ cells compared to wild type, demonstrating the importance of optimized detection methods .

How should researchers interpret changes in ERG4 localization under different experimental conditions?

When analyzing localization changes:

• Quantitative approach:

  • Use colocalization coefficients (Pearson's, Mander's)

  • Measure fluorescence intensity across cellular compartments

  • Apply consistent thresholding between samples

• Distinguishing factors:

  • Compare with ER morphology markers to differentiate between general ER changes and specific ERG4 redistribution

  • Analyze both membrane and cytosolic fractions to detect potential protein mislocalization

  • Consider protein degradation effects on apparent localization

• Interpretation guidelines:

  • In wild-type cells, ERG4 should predominantly localize to the ER membrane

  • Shifts to cytosolic fractions may indicate protein misfolding or failed membrane insertion

  • Changes in ER morphology may affect apparent ERG4 distribution

In yeast lacking Bfr1p, Erg4p shifts from the membrane to cytosolic fractions, indicating impaired ER insertion or protein stability issues .

How does the ERAD pathway affect ERG4 protein levels and how can this be studied experimentally?

The endoplasmic reticulum-associated degradation (ERAD) pathway regulates ERG4 protein levels under certain conditions. Research approaches include:

• Genetic manipulation:

  • Create double deletion strains (e.g., bfr1Δ hrd1Δ) to block ERAD components

  • Measure protein accumulation with proteasome inhibitors like MG132

• Degradation kinetics:

  • Perform cycloheximide chase experiments to measure protein half-life

  • Compare degradation rates between wild-type and ERAD-deficient backgrounds

  • Block translation with cycloheximide (CHX) at different time points to track degradation

• Quantitative analysis:

  • Western blotting with densitometry to measure protein levels

  • Compare accumulation patterns across different genetic backgrounds

Research has shown that in bfr1Δ cells, Erg4p is misfolded and targeted by the ERAD pathway, with significantly increased accumulation in double deletion strains (bfr1Δ hrd1Δ) treated with MG132 .

How can researchers investigate the relationship between ERG function and cellular signaling pathways?

For studying ERG functional relationships with signaling pathways:

• Phosphorylation analysis:

  • Examine effects of phosphomimetic mutations (e.g., S96E in human ERG)

  • Test resistance to pathway inhibitors (e.g., TAK-242 for TLR4 inhibition)

  • Analyze downstream transcriptional effects

• Signaling pathway manipulation:

  • Use small molecule inhibitors of specific pathways

  • Apply genetic approaches (knockdown/knockout of pathway components)

  • Measure effects on ERG-dependent phenotypes and target gene expression

• Transcriptional readouts:

  • Employ luciferase reporter assays with ERG-responsive elements

  • Perform RT-qPCR on direct ERG target genes

  • Analyze effects of pathway inhibition on ERG-dependent transcription

Research has demonstrated that TLR4 signaling activates ERG function in prostate cells, with inhibition of this pathway reducing ERG's ability to activate transcriptional targets .

What methods can determine if an antibody blocks protein-ligand interactions?

To assess if an antibody blocks protein-ligand interactions:

• Functional assays:

  • Measure downstream signaling activation (phosphorylation events)

  • Analyze biological responses (proliferation, migration, survival)

  • Compare effects with known inhibitors or genetic knockdowns

• Binding studies:

  • Perform competitive binding assays with labeled ligands

  • Use surface plasmon resonance (SPR) to measure binding kinetics

  • Apply ELISA-based approaches to detect ligand-receptor complexes

• Structural analysis:

  • Map epitope locations relative to ligand-binding domains

  • Use hydrogen-deuterium exchange mass spectrometry to assess conformational changes

  • Consider in silico modeling of antibody-antigen interactions

Antibody-based therapies often target receptors like ErbB4 to block neuregulin-dependent activation, inhibiting downstream signaling and cancer cell proliferation .

How do expression patterns of ERG4 variants differ between fungal species and what experimental approaches can address these differences?

When studying ERG4 variants across species:

Research approaches include:

• Cross-species complementation: Test functional redundancy by expressing variants across species

• Promoter analysis: Characterize regulatory elements controlling differential expression

• Evolutionary analysis: Perform phylogenetic comparisons to identify conserved functional domains

In P. expansum, deleting individual ERG4 variants triggers compensatory expression changes in the remaining variants, indicating functional redundancy but specialized regulatory mechanisms .

How does antibody selection differ when studying ERG proteins in human cancer versus ERG4 in fungal systems?

Key considerations for antibody selection across different research systems:

• Epitope conservation:

  • Human ERG antibodies target transcription factor domains

  • Fungal ERG4 antibodies target sterol reductase domains

  • Cross-species reactivity must be carefully validated

• Application-specific requirements:

  • Cancer tissue studies often require antibodies validated for immunohistochemistry

  • Fungal studies may prioritize antibodies optimized for fractionation and membrane protein detection

  • Different fixation protocols may require specific antibody characteristics

• Experimental readouts:

  • Human ERG studies often examine nuclear localization and transcriptional activity

  • Fungal ERG4 studies focus on ER membrane localization and ergosterol biosynthesis

Human studies have successfully used antibodies targeting specific phosphorylation sites (e.g., S96) to study ERG activation states in prostate cancer cells .